Tag: corifact market key players

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Corifact Market CAGR Outlook And Future Development

Historically, the expansion has been linked to the identification of fibrinogen deficiency, advancements in trauma care, refined surgical bleeding management protocols, the approval of plasma-derived therapies, and broader hospital adoption.

Anticipated growth over the forecast horizon is driven by an increase in emergency surgical procedures, the requirements of an aging demographic, the proliferation of trauma facilities, advancements in blood coagulation assessment, and a heightened need for quick-acting hemostatic solutions.

Significant trends anticipated include a greater utilization of fibrinogen concentrates, an emphasis on achieving swift hemorrhage management, the broadening scope of trauma and surgical services, hemostasis oversight primarily within hospital settings, and growing implementation in therapeutic approaches for liver conditions.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=98548660&type=smp&name=Corifact%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Corifact Market Industry Drivers: What’s Behind The Revenue Growth?

The expanding occurrence of bleeding disorders is projected to stimulate the growth of the corifact market moving forward. Bleeding disorders are medical conditions that hinder the blood’s proper clotting mechanism, leading to either excessive or prolonged bleeding. The increase in these disorders can be ascribed to enhanced diagnostic capabilities, greater public awareness, breakthroughs in genetic testing, along with shifts in lifestyle and the existence of underlying health issues. Corifact provides treatment for bleeding disorders caused by factor XIII deficiency by substituting the absent clotting factor, thereby assisting in the formation of stable blood clots and diminishing excessive bleeding. For instance, in December 2023, according to a report from the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), a UK-based organization, the 2023/24 period demonstrated the significant impact of bleeding disorders, with 6,835 individuals identified with haemophilia A, 1,378 with haemophilia B, alongside 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the rising prevalence of bleeding disorders is a significant factor propelling the expansion of the corifact market.

Corifact Market Segment Performance And Emerging Opportunities

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Corifact Market Key Players: Which Companies Lead Industry Competition?

Major companies operating in the corifact market are CSL Behring

View The Full Corifact Market Report:

https://thebusinessresearchcompany.com/report/corifact-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Corifact Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Corifact Market Revenue Outlook: What CAGR Is Expected Through 2030?

The expansion observed during the historic period was driven by the increased identification of fibrinogen deficiency, progress in trauma care, standardized protocols for managing surgical bleeding, regulatory approvals for plasma-derived treatments, and the integration of these therapies into hospital practices.

The projected expansion during the forecast period is driven by a rise in emergency surgical procedures, the requirements of an aging demographic, the broadening of trauma center capabilities, advancements in coagulation testing, and a growing need for fast-acting hemostatic products. Key developments shaping this period involve the growing application of fibrinogen concentrates, a heightened emphasis on swift hemorrhage management, the widening scope of trauma and surgical services, the implementation of hospital-focused hemostasis control programs, and increased usage in the management of liver disorders.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Corifact Market Opportunity Drivers: What Is Creating New Revenue Potential?

The growing occurrence of bleeding disorders is anticipated to drive forward expansion within the corifact market. Such disorders hinder the blood’s capacity to clot effectively, resulting in extended or excessive bleeding episodes. This uptick in bleeding conditions stems from enhanced diagnostic capabilities, broader public awareness, progress in genetic screening, shifts in lifestyle habits, and the presence of underlying health issues. Corifact addresses factor XIII deficiency-related bleeding disorders by supplying the absent clotting factor, enabling the formation of stable clots and minimizing excessive blood loss. As reported in December 2023 by the United Kingdom Haemophilia Centre Doctors’ Organisation—a UK entity—the 2023/24 data underscores the bleeding disorder burden, listing 6,835 people with haemophilia A, 1,378 with haemophilia B, 1,845 carriers of haemophilia A, 892 women with factor VIII deficiency, and 390 carriers of haemophilia B. Consequently, the escalating prevalence of these disorders fuels growth in the corifact market.

Growing consumer interest in biological products is set to stimulate progress in the corifract market moving forward. These products are intricate pharmaceutical agents sourced from living organisms, employed for diagnosing, preventing, treating, or curing diseases and medical conditions. Heightened demand for them results from increasing environmental consciousness, more informed consumer choices, and a push for sustainable, effective alternatives to synthetic compounds. Corifract enhances biological products by improving their stability, absorption, and effectiveness, guaranteeing optimal results and extended usability via creative formulation and delivery methods. According to an August 2025 report from the Assistant Secretary for Planning and Evaluation—a US government agency—biosimilar net revenue can range from a USD 33.5 million loss in small markets to USD 9.5 billion in large ones, while proposed changes like universal interchangeability, a global comparator, and removing comparative efficacy studies could reduce development costs by USD 2 billion, raise lifetime revenues by USD 13.5 million, and add USD 84 million, respectively. Thus, rising demand for biological products propels the corifract market.

A higher volume of surgical interventions is forecasted to accelerate growth in the corifact market. These procedures involve medical operations carried out by clinicians to address injuries, diseases, or abnormalities via manual or instrument-based techniques. The increase in surgeries is largely driven by an aging population needing care for age-linked conditions and progress in minimally invasive technologies, which enhance safety and accessibility. Corifact is utilized during surgeries to manage and stop excessive bleeding in patients with congenital Factor XIII deficiency, aiding clot stabilization and wound healing. As reported in June 2024 by the American Society of Plastic Surgeons—a US professional organization—minimally invasive procedures grew 7 percent in 2023, outpacing surgical ones by 2 percent, with neuromodulator injections and hyaluronic acid fillers reaching over 9 million and 5 million treatments each. Therefore, the expanding number of surgical procedures supports corifact market expansion.

Corifact Market Segment Analysis Highlighting Growth Areas

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Corifact Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the corifact market are CSL Behring

Access The Complete Corifact Market Report:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Corifact Market Geographic Distribution And Regional Opportunities

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Corifact Market Over The Forecast Period?

Historical expansion was driven by the identification of fibrinogen deficiency, progress in trauma treatment, enhanced protocols for managing surgical bleeding, regulatory approvals for plasma-derived therapies, and widespread acceptance by hospitals.

Growth in the forecast period is projected to stem from an increase in emergency surgical procedures, the evolving demands of an aging demographic, the expansion of trauma care facilities, improvements in coagulation diagnostics, and a heightened need for rapid hemostatic agents. Simultaneously, key trends anticipated for this period encompass the expanded application of fibrinogen concentrates, an intensified focus on swift bleeding management, the broadening of trauma and surgical care services, the implementation of hospital-based hemostasis management strategies, and rising adoption in the treatment of liver diseases.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

What Influential Factors Are Boosting The Corifact Market Demand?

The corifact market is anticipated to expand due to the rising occurrence of bleeding disorders, which are conditions that hinder the blood’s proper clotting, causing excessive or extended bleeding. The escalation in these disorders stems from enhanced diagnosis, greater public awareness, breakthroughs in genetic testing, along with shifts in lifestyle and the presence of underlying health issues. Corifact addresses bleeding disorders resulting from factor XIII deficiency by supplying the absent clotting factor, thereby aiding in the formation of stable blood clots and diminishing excessive bleeding. For example, a December 2023 report from the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), a UK-based entity, highlighted the impact of bleeding disorders in 2023/24, noting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, in addition to 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the growing prevalence of bleeding disorders is fueling the growth of the corifact market. The corifract market is projected to grow due to the increasing demand for biological products, which are intricate pharmaceutical agents sourced from living organisms for diagnosing, preventing, treating, and curing various diseases and medical ailments. This increased demand for biological products is linked to heightened environmental concerns, greater consumer understanding, and the necessity for sustainable and efficient alternatives to man-made chemicals. Corifract aids biological products by improving their stability, bioavailability, and effectiveness, thereby guaranteeing peak performance and extended shelf life through advanced formulation and delivery methods. For example, in August 2025, the Assistant Secretary for Planning and Evaluation, a US government department, reported that biosimilar net revenue could range from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger markets, with proposed regulatory adjustments such as universal interchangeability, a global comparator, and the elimination of comparative efficacy studies expected to reduce development costs and increase lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Thus, the growing demand for biological products is propelling the corifract market.

Which Segment Groups Define The Corifact Market Landscape?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Who Are The Firms Contributing To The Corifact Market Ecosystem?

Major companies operating in the corifact market are CSL Behring

Access The Complete Corifact Market Report:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

Which Region Is The Primary Market For The Corifact Market?

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Corifact Market Expected To Change From 2026 To 2030?

The expansion observed in the historic period was driven by the identification of fibrinogen deficiency, developments in trauma care, established protocols for surgical bleeding management, the authorization of plasma-derived therapies, and their subsequent incorporation by hospitals.

The expansion projected during the forecast period is driven by a surge in emergency operations, the growing demands of an aging population, the enlargement of trauma facilities, enhancements in coagulation diagnostic methods, and the escalating need for quick-acting hemostatic solutions.

Significant patterns emerging in the forecast period encompass an uptick in the utilization of fibrinogen concentrates, a primary emphasis on achieving rapid bleeding control, the proliferation of trauma and surgical treatment options, the implementation of hemostasis management within hospital settings, and a growing application in the management of liver diseases.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

Which Key Factors Are Driving The Corifact Market Growth?

The growing incidence of bleeding disorders is projected to boost the corifact market. These conditions hinder the blood’s ability to clot effectively, leading to excessive or prolonged bleeding. The increase in bleeding disorders stems from enhanced diagnosis, greater awareness, genetic testing advancements, lifestyle shifts, and the presence of underlying health issues. Corifact addresses bleeding disorders caused by factor XIII deficiency by substituting the absent clotting factor, thereby aiding in the formation of stable blood clots and diminishing excessive bleeding. For example, in December 2023, a report from the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), a UK-based entity, highlighted the burden of bleeding disorders in 2023/24, noting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, alongside 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the rising occurrence of bleeding disorders is a significant driver for the corifact market. A rising demand for biological products is set to propel the growth of the corifract market. Biological products are intricate pharmaceutical substances derived from living organisms, utilized for diagnosing, preventing, treating, and curing various diseases and medical conditions. This surge in demand for biological products is linked to heightened environmental concerns, increased consumer awareness, and the necessity for sustainable and effective alternatives to synthetic chemicals. Corifract contributes to biological products by enhancing their stability, bioavailability, and efficacy, ensuring optimal performance and extended shelf life through advanced formulation and delivery solutions. As an illustration, in August 2025, the Assistant Secretary for Planning and Evaluation, a US government department, stated that net revenue for biosimilars could range from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger ones. Proposed regulatory adjustments, including universal interchangeability, a global comparator, and the removal of comparative efficacy studies, are estimated to reduce development costs and increase lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Hence, the escalating demand for biological products is driving the corifract market.

What Segment Categories Shape The Corifact Market Segment Landscape?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Who Are The Companies Operating Across The Corifact Market Value Chain?

Major companies operating in the corifact market are CSL Behring

Get The Full Corifact Market Report:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

Which Region Is The Top Contributor To The Corifact Market By Share?

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Corifact Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

Browse Through More Reports Similar to the Global Corifact Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Consumer Credit Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-credit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Corifact Market During The Forecast Period 2026–2030?

Historically, growth was primarily driven by the increased awareness of fibrinogen deficiency, alongside significant advancements in trauma care, enhanced surgical bleeding management protocols, the approval of plasma-derived therapies, and their widespread adoption by hospitals.

The anticipated growth during the forecast period is primarily fueled by an increase in emergency surgical procedures, the requirements of an aging demographic, the expansion of trauma centers, advancements in coagulation diagnostic methods, and a rising demand for swift-acting hemostatic agents. Concurrently, significant developments anticipated in this period include a greater reliance on fibrinogen concentrates, an intensified focus on quickly managing bleeding, an expansion in trauma and surgical healthcare services, the implementation of hospital-centric hemostasis management strategies, and an increasing application in the treatment of liver diseases.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

Which Economic Or Industry Drivers Are Impacting The Corifact Market?

The expanding occurrence of bleeding disorders is projected to boost the corifact market’s future growth. These conditions hinder the blood’s proper clotting, resulting in excessive or prolonged bleeding. The uptick in bleeding disorders stems from enhanced diagnosis, greater public awareness, advancements in genetic testing, alongside evolving lifestyles and existing underlying health issues. Corifact addresses bleeding disorders stemming from factor XIII deficiency by substituting the absent clotting factor, thus assisting in the formation of stable blood clots and mitigating excessive bleeding. For example, in December 2023, a report from the UK-based United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) highlighted the prevalence of bleeding disorders in 2023/24, documenting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, in addition to 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the rising incidence of bleeding disorders is fueling the expansion of the corifact market. An increased demand for biological products is anticipated to spur the future growth of the corifract market. Biological products are intricate pharmaceutical compounds originating from living organisms, utilized for diagnosing, preventing, treating, and curing various illnesses and medical conditions. This surge in demand for biological products is linked to escalating environmental worries, enhanced consumer consciousness, and the necessity for sustainable and efficient substitutes for synthetic chemicals. Corifract aids biological products by boosting their stability, bioavailability, and effectiveness, thereby guaranteeing peak performance and extended shelf life through cutting-edge formulation and delivery methods. As an illustration, in August 2025, the Assistant Secretary for Planning and Evaluation, a US government department, reported that biosimilar net revenue could range from a USD 33.5 million deficit in smaller markets to USD 9.5 billion in larger markets. Furthermore, proposed regulatory revisions, such as universal interchangeability, a global comparator, and the elimination of comparative efficacy studies, are projected to reduce development costs and elevate lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Thus, the growing demand for biological products is propelling the corifract market.

What Market Segments Are Evaluated Within The Corifact Market?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Who Are The Top Market Participants Influencing The Corifact Market?

Major companies operating in the corifact market are CSL Behring

Read the full corifact market report here:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

What Are The Top-Performing Regions Within The Corifact Market?

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Corifact Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20024&type=smp

Browse Through More Reports Similar to the Global Corifact Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Consumer Credit Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-credit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the corifact market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Corifact Market covering 2026–2035?

The expansion observed historically stems from the identification of fibrinogen deficiency, advancements in trauma care, refined protocols for managing surgical bleeding, approvals of plasma-derived therapies, and their widespread adoption by hospitals.

The projected growth during the forecast period is driven by an increase in emergency surgical procedures, the specific needs of an aging population, the expansion of trauma centers, advancements in coagulation diagnostics, and a growing demand for rapid hemostatic agents.

Significant trends expected in the forecast period include a greater adoption of fibrinogen concentrates, an increased focus on achieving swift bleeding control, the broader expansion of trauma and surgical care services, the implementation of hospital-based hemostasis management, and a rising application in the treatment of liver diseases.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Corifact Market?

The corifact market is projected to expand due to the rising occurrence of bleeding disorders. These disorders are medical conditions that hinder the blood’s natural clotting ability, leading to prolonged or excessive blood loss. The increase in these conditions stems from enhanced diagnostic methods, greater public awareness, breakthroughs in genetic testing, along with shifts in lifestyle and the prevalence of underlying health issues. Corifact provides treatment for bleeding disorders resulting from factor XIII deficiency by supplying the missing clotting factor, which aids in forming stable blood clots and lessening profuse bleeding. As an illustration, in December 2023, data from the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), a UK-based body, indicated the extent of bleeding disorders in 2023/24, documenting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, in addition to 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the growing incidence of bleeding disorders is a key factor propelling the corifact market’s expansion. The expanding demand for biological products is set to fuel the growth of the corifract market moving forward. Biological products are intricate pharmaceutical compounds derived from living organisms, utilized for diagnosing, preventing, treating, and curing various illnesses and health conditions. The escalating need for biological products can be attributed to growing environmental concerns, heightened consumer understanding, and the imperative for sustainable, effective alternatives to synthetic chemicals. Corifract plays a crucial role in supporting biological products by improving their stability, bioavailability, and effectiveness, thereby guaranteeing optimal performance and extended shelf life through cutting-edge formulation and delivery approaches. For example, in August 2025, according to the Assistant Secretary for Planning and Evaluation, a US-based government department, net revenue for biosimilars could range from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger ones; moreover, proposed regulatory modifications, including universal interchangeability, a global comparator, and the elimination of comparative efficacy studies, are estimated to reduce development expenses and boost lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Thus, the increasing uptake of biological products is a significant driver for the corifract market.

What Leading Segments Are Studied In The Corifact Market?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Which Major Firms Are Strengthening Their Position In The Corifact Market?

Major companies operating in the corifact market are CSL Behring

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Corifact Market?

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Corifact Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20024&type=smp

Browse Through More Reports Similar to the Global Corifact Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Consumer Credit Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-credit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Corifact Market In 2029?

In recent years, the market size for Corifact has grown XX (HCAGR). The market is projected to expand from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. This growth during the historical period can be credited to increased usage of Factor XIII concentrates, bettered awareness, heightened automation, an increased demand for expanded care delivery, and the implementation of fresh plasma fractionation technologies.

What Growth Rate Is Forecasted for the Corifact Market by 2029?

Predictions suggest that the Corifact market size is set to expand at a XX (FCAGR) in the upcoming years, reaching $XX million in 2029 with a compound annual growth rate (CAGR) of XX%. Such growth during the forecast period is primarily due to the heightened occurrence of bleeding disorders, improved understanding and early detection, an increase in surgical operations, heightened reliance of the client base, and an elongated half-life of the factor VIII. Key trends for the forecast period include technological progression, improvements in healthcare infrastructure, innovative techniques in developing recombinant therapies, progression in biotechnology, and the FDA’s endorsement of Corifact.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

Which Key Companies Are Shaping the Future of the Corifact Market?

Major companies operating in the corifact market include CSL Behring

Which Factors Are Driving Demand in the Corifact Industry?

The growth of the corifact market is likely to be fuelled by the rising occurrence of bleeding disorders. These disorders, which hinder the blood’s ability to clot effectively and result in prolonged or severe bleeding, are increasing due to factors such as better diagnosis, heightened awareness, advancements in genetic testing, lifestyle alterations, and the incidence of predisposing conditions. Corifact works as a treatment for bleeding disorders caused by factor XIII deficiency, serving to replace the absent clotting factor and thus promote the formation of sturdy blood clots while curbing severe bleeding. For example, a World Federation of Hemophilia Report published in October 2023 revealed that in 2022, a global count of 427,685 individuals were identified to have bleeding disorders. This figure included 257,146 hemophilia cases (split into 208,957 of hemophilia A, 42,203 of hemophilia B, and 5,986 unspecified), 100,505 cases of von Willebrand disease, and 70,034 cases of other bleeding disorders. As such, the escalation in the prevalence of bleeding disorders is stimulating the expansion of the corifact market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20024&type=smp

How Is the Corifact Market Segmented by Several Divisions?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

Which Regions Are Driving Growth in the Corifact Market?

North America was the largest region in the corifact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20024

This Report Delivers Insight On:

1. How big is the corifact market, and how is it changing globally?

2. Who are the major companies in the corifact market, and how are they performing?

3. What are the key opportunities and risks in the corifact market right now?

4. Which products or customer segments are growing the most in the corifact market?

5. What factors are helping or slowing down the growth of the corifact market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theCorifact Market?

The rising prevalence of bleeding disorders is expected to boost the growth of the corifact market. Bleeding disorders impair the blood’s ability to clot, leading to excessive bleeding. Factors such as improved diagnosis, increased awareness, genetic testing advancements, and lifestyle changes contribute to their rise. Corifact helps treat bleeding disorders by replacing missing clotting factors. The World Federation of Hemophilia’s 2023 report highlighted that 427,685 individuals were diagnosed with bleeding disorders worldwide in 2022, including hemophilia, von Willebrand disease, and other types. This increasing prevalence is driving market growth.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

#What Are the Key Projections for the CAGR of the Corifact Market From 2025 to 2034?

The corifact market has shown XX (HCAGR) in prior years. It is forecasted to expand from $XX million in 2024 to $XX million in 2025 at a CAGR of XX%. Contributing factors to historic growth include greater usage of factor XIII concentrates, heightened awareness, more automation, rising demand for extended care, and newer plasma fractionation methods.

The corifact market is expected to record XX (FCAGR) over the coming years, growing to $XX million by 2029 at a CAGR of XX%. Growth drivers include the increasing prevalence of bleeding disorders, better awareness and early diagnosis, more surgeries, growing reliance on client bases, and longer half-life of factor VIII. Trends include healthcare infrastructure improvements, biotech advancements, recombinant therapy innovations, and FDA approvals.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20024

Who Are the Dominant Market Players Pushing the Boundaries of theCorifact Market?

Major companies operating in the corifact market include CSL Behring

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

What Are the Core Segments of the Corifact Market, and How Do They Contribute to Growth?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20024&type=smp

What Regions Are Dominating the Corifact Market Growth?

North America was the largest region in the corifact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Corifact Market 2025, By The Business Research Company:

Encephalitis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/encephalitis-treatment-global-market-report

Epidural Abscess Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/epidural-abscess-treatment-global-market-report

Keloids Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the corifact market grown over the years?

In recent years, the corifact market size has exhibited an HCAGR of XX. The market is projected to expand from $XX million in 2024 to $XX million in 2025, showcasing a compound annual growth rate (CAGR) of XX%. The growth observed in the historic timeframe can be linked to a higher usage of factor XIII concentrates, enhanced awareness, advanced automation, the need for extended care delivery, and the acceptance of novel plasma fractionation technologies.

What Is the forecasted market size and growth rate for the corifact market?

The market size of Corifact is predicted to experience an XX% (FCAGR) uptick over the upcoming years, reaching a projected value of $XX million in 2029. This significant rise is attributed to the increasing incidence of bleeding disorders, heightened awareness and early detection, an increase in surgical operations, a growing dependency on client base, and the elongated half-life of factor VIII. Notable trends over this forecast period including technological progress, improvements in healthcare infrastructure, innovative methodologies in developing recombinant therapies, advances in biotechnology, and the FDA’s approval of Corifact.

Get your corifact market report here!

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

What are the major factors driving growth in the corifact market?

The escalating incidence of blood clotting disorders is predicted to fuel the corifact market’s expansion. These disorders, which hinder the blood’s clotting ability, result in prolonged or excessive bleeding. Enhanced diagnostic techniques, greater awareness, advancements in genetic tests, lifestyle modifications, and the presence of contributory conditions are all factors contributing to the surge in clotting disorders. Corifact is used to manage blood clotting disorders stemming from a deficiency in factor XIII by replacing the absent clotting agent, thus aiding in the formation of stable clots and minimizing excessive bleeding. For instance, a World Federation of Hemophilia Report published in October 2023 revealed that in 2022, a whopping 427,685 individuals across the globe were diagnosed with clotting disorders. The statistics included 257,146 hemophilia cases- 208,957 hemophilia A, 42,203 hemophilia B, and 5,986 unspecified types. Additionally, there were 100,505 cases of von Willebrand disease and 70,034 instances of other clotting disorders. Therefore, the escalating incidence of these disorders is facilitating the corifact market’s growth.

What key areas define the segmentation of the global corifact Market?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

What are the top market players propelling the growth of the corifact industry?

Major companies operating in the corifact market include CSL Behring

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20024

What regions are dominating the corifact market growth?

North America was the largest region in the corifact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Encephalitis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/encephalitis-treatment-global-market-report

Epidural Abscess Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/epidural-abscess-treatment-global-market-report

Keloids Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR Will the Corifact Market Achieve During 2025–2034, and What Does It Indicate?

In recent times, the corifact market has seen a (CAGR) of XX. The market is anticipated to expand from a size of $XX million in 2024, climbing to $XX million in 2025 at a Compound Annual Growth Rate (CAGR) of XX%. This growth in past years is the result of increased usage of factor XIII concentrates, heightened awareness, greater automation, the need for enhanced care delivery, and the implementation of the latest plasma fractionation technologies.

The corifact market is projected to experience an XX (CAGR) surge in the coming years, ballooning to $XX million by 2029 with a compound annual growth rate (CAGR) of XX%. This growth in the forecast period is attributable to factors such as rising prevalence of bleeding disorders, heightened awareness and early diagnosis, an increase in surgical procedures performed, an expanding reliant client base, and increased half-life of factor VIII. Significant trends in the forecast period include technological innovations, improvements in healthcare infrastructure, inventive methods for developing recombinant therapies, progress in biotechnology, and Corifact’s FDA approval.

What Drivers Are Shaping the Growth of the Corifact Market?

The escalating frequency of bleeding disorders is projected to push the growth of the corifact market. Conditions impairing the blood’s coagulation mechanism, leading to significant or prolonged bleeding, are known as bleeding disorders. The surge in these disorders can be owed to several factors such as better diagnostic techniques, enhanced awareness, progress in genetic testing, lifestyle alterations, and the widespread presence of core conditions. Corifact offers treatment for bleeding disorders stemming from factor XIII deficiencies by supplanting the lacking clotting element. In turn, it aids in constructing stable blood clots and minimizes excessive bleeding. For example, the World Federation of Hemophilia Report published a report in October 2023 stating that in 2022, approximately 427,685 people globally were identified with bleeding disorders. These figures included 257,146 hemophilia diagnoses (208,957 hemophilia A, 42,203 hemophilia B, and 5,986 cases unspecified), 100,505 cases of von Willebrand disease, and 70,034 instances of other bleeding disorders. Consequently, the escalating frequency of bleeding disorders contributes to the expansion of the corifact market.

Request Your Free Corifact Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

Who Are the Key Firms Paving the Way for Growth in the Corifact Market?

Major companies operating in the corifact market include CSL Behring

Get Instant Access to the Global Corifact Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

What Are the Major Segments of the Corifact Market and Their Role in Driving Growth?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Which Regions Are Essential for the Growth of the Corifact Market?

North America was the largest region in the corifact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Scope and Reach of the Corifact Market Defined?

Corifact refers to a fibrinogen concentrate used in medical treatments to manage bleeding, particularly in patients with fibrinogen deficiency or low fibrinogen levels, which can occur in conditions such as trauma, surgery, or liver disease. Corifact helps to promote blood clotting by providing fibrinogen, a protein essential for the formation of blood clots.

Browse Through More Similar Reports By The Business Research Company:

Encephalitis Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/encephalitis-treatment-global-market-report

Epidural Abscess Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/epidural-abscess-treatment-global-market-report

Keloids Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: